Search results

232 results

Sorted by Relevance . Sort by Date

  1. Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee (TA508)

    Evidence-based recommendations on autologous chondrocyte implantation (ACI) using chondrosphere (Spherox) for symptomatic articular knee cartilage defects

  2. Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (TA505)

    Evidence-based recommendations on ixazomib (Ninlaro), with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma in adults

  3. Ceritinib for untreated ALK-positive non-small-cell lung cancer (TA500)

    Evidence-based recommendations on ceritinib (Zykadia) for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC)

  4. Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (TA540)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating relapsed or refractory classical Hodgkin lymphoma in adults

  5. Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib (TA586)

    Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for multiple myeloma after 1 treatment with bortezomib in adults

  6. Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (TA584)

    Evidence-based recommendations on atezolizumab (Tecentriq) with bevacizumab (Avastin), carboplatin and paclitaxel for metastatic non-squamous non-small-cell

  7. Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA600)

    Evidence-based recommendations on pembrolizumab (Keytruda) with carboplatin and paclitaxel for adults with untreated metastatic squamous non-small-cell lung

  8. Dapagliflozin with insulin for treating type 1 diabetes (TA597)

    Evidence-based recommendations on dapagliflozin (Forxiga) with insulin for treating type 1 diabetes not controlled by insulin therapy alone in adults with a

  9. Letermovir for preventing cytomegalovirus disease after a stem cell transplant (TA591)

    Evidence-based recommendations on letermovir (Prevymis) for preventing cytomegalovirus (CMV) disease after a stem cell transplant in adults

  10. Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine (TA535)

    Evidence-based recommendations on lenvatinib (Lenvima) and sorafenib (Nexavar) for progressive, locally advanced or metastatic differentiated thyroid cancer in

  11. Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)

    Evidence-based recommendations on ixekizumab (Taltz) for treating active psoriatic arthritis after inadequate response to DMARDs in adults

  12. Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543)

    Evidence-based recommendations on tofacitinib (Xeljanz) for treating active psoriatic arthritis after inadequate response to DMARDs in adults

  13. Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma (TA544)

    Evidence-based recommendations on dabrafenib (Tafinlar) with trametinib (Mekinist) for resected stage III, BRAF V600 mutation-positive melanoma in adults

  14. Gemtuzumab ozogamicin for untreated acute myeloid leukaemia (TA545)

    Evidence-based recommendations on emtuzumab oxogamicin (Mylotarg) for untreated acute myeloid leukaemia (AML) in people aged 15 years and over

  15. Tofacitinib for moderately to severely active ulcerative colitis (TA547)

    Evidence-based recommendations on tofacitinib (Xeljanz) for previously treated moderately to severely active ulcerative colitis in adults

  16. Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours (TA539)

    Evidence-based recommendations on lutetium (177Lu) oxodotreotide (Lutathera) for treating unresectable or metastatic neuroendocrine tumours in adults

  17. Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia (TA541)

    Evidence-based recommendations on inotuzumab ozogamicin (Besponsa) for relapsed/refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia (ALL)

  18. Sotagliflozin with insulin for treating type 1 diabetes (TA622)

    Evidence-based recommendations on sotagliflozin with insulin for treating type 1 diabetes in adults with a body mass index (BMI) of at least 27 kg/m2

  19. Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis (TA624)

    Evidence-based recommendations on peginterferon beta-1a (Plegridy) for treating relapsing–remitting multiple sclerosis in adults

  20. Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA619)

    Evidence-based recommendations on palbociclib (Ibrance) with fulvestrant for hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer

  21. Lanadelumab for preventing recurrent attacks of hereditary angioedema (TA606)

    Evidence-based recommendations on lanadelumab (Takhzyro) for preventing recurrent attacks of hereditary angioedema in people aged 12 and over

  22. Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (TA221)

    Evidence-based recommendations on romiplostim (Nplate) for treating chronic immune (idiopathic) thrombocytopenic purpura (ITP)